Sinovac Biotech Ltd (SVA)

[StockRoomBully]

$Sbmff

Sino Biopharmaceutical: Investing In China's COVID-19 Vaccine While Sinovac Remains Halted
Dec. 12, 2020 10:28 AM

Sino Biopharmaceutical Limited ($SBMFF)AZN, AZNCF, CASBF
Summary

Sinovac Biotech has developed a successful COVID-19 vaccine, CoronaVac, directly competing with two Chinese rivals, Pfizer, AstraZeneca, Moderna and Russia's Sputnik V.
Nasdaq and Hong Kong-listed partner Sino Biopharm providing $515 million funding for 15.03% equity stake in Sinovac.

Sinovac's Nasdaq listing currently still halted after attack from activist shareholders.


Way forward unclear, but SEC seemingly supporting Sinovac's version of events. In the meantime, CoronaVac has been approved and currently in use in several countries.


Best opportunity to invest in CoronaVac's success is through Sino Biopharm.

One company that may have a promising lead on a COVID-19 vaccine, alongside international rivals such as Pfizer (PFE), AstraZeneca (AZN), Moderna (MRNA) and Camaleya's Sputnik V, is Sinovac Biotech (SVA), a Chinese biotechnology firm. Since mid-2020, the vaccine called 'CoronaVac' has been undergoing Phase III clinical research.

On October 19, preliminary results from the Phase III trial in Brazil showed CoronaVac appeared to be safe in providing protection against COVID-19.

By December 3, over a million doses of CoronaVac had arrived in Brazil.

https://seekingalpha.com/amp/article/4394397-sino-biopharmaceutical-investing-in-chinas-covidminus-19-vaccine-while-sinovac-remains-halted